Adjuvant Treatment with Dienogest Significantly Reduces Postoperative Recurrence in Endometriosis

calendar
12 May, 23

Introduction

Dienogest is a 4th generation of highly selective progesterone receptor agonist and has been proved safe and effective postoperative treatment in endometriosis in Asia. However, this study will compare the efficacy of dienogest with gonadotrophin releasing hormone agonists (GnRH-a), as adjuvant drugs in endometriosis patients after laparoscopic surgery

 

Aim

To compare the efficacy of Dienogest and GnRH- a after endometriosis surgery

 

Method

 

Study Design

  • Prospective clinical study

 

Treatment Strategy

  • A total of 81 patients with endometriosis after conservative laparoscopic surgery were randomly assigned to control and observation group

  • Control group comprised 40 women, treated with GnRH-a 3.75 mg on day 1 of menstrual cycle and repeated after every 28 days for 3 months

  • Observational group included 41 women, treated with dienogest 2 mg twice daily at 3 to 5 days after surgery and then once daily for 6 months

 

Endpoints

  • Pain evaluated by VAS score and Kupperman score

  • Estradiol (E2) levels at 3 and 6 months

  • Follicle stimulating hormone (FSH) levels at 3 and 6 months

  • Days of vaginal bleeding

  • Rate of recurrence at 3 and 6 months

 

Results 

  • Age and the cyst size was comparable between the 2 groups

  • Both the groups had a significant reduction in pain as seen in table 1.

 

Table 1. Comparison of VAS and Kupperman scores before and after surgery

 
 
 
 
 
 
 

 

 
 
 
 

Control group

 
 
 
 

Observational group

 
 
 
 

VAS score

 
 
 
 

Before treatment

 
 

5.65+2.47

 
 

4.29+2.02

 
 
 
 

3 months

 
 

1.8+1.57

 
 

1.61+1.48

 
 
 
 

6 months

 
 

0.78+0.8

 
 

0.73±0.78

 
 
 
 

P value

 
 

<0.05

 
 

<0.05

 
 
 
 

Kupperman score

 
 
 
 

Before treatment

 
 

12.4+5.62

 
 

11.88+5.47

 
 
 
 

3 months

 
 

3.9+1.84

 
 

3+1.86

 
 
 
 

6 months

 
 

3.9+1.84

 
 

1.55+1.24

 
 
 
 

P value

 
 

<0.05

 
 

<0.05

  • The days of vaginal bleeding significantly reduced after treatment with adjuvant GnRH-a and dienogest

  • Normal values of E2 and FSH were attained 6 months post-surgery with both the drugs

  • Postoperative recurrence was remarkably higher in the control group; p<0.05 as seen in Figure 1.

  • Treatment with dienogest was associated with higher efficacy 82.9% vs 77.5%; p<0.05

  • Overall effectiveness of treatment is shown in Figure 1.

 

Figure 1. Overall effectiveness of treatment

 

Conclusion

  • Postoperative adjuvant treatment with dienogest significantly reduces the postoperative recurrence as compared to gonadotrophin releasing hormone agonist (GnRH-a)

  • Dienogest was equally effective as GnRH-a in providing pain relief, reducing the vaginal bleeding and achieving normal estradiol and FSH levels after laparoscopic surgery

 

BMC Womens Health. 2023 Feb 24;23(1):85.